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ABSTRACT
In eukaryotic cells, the shortening and removal
of the poly(A) tail of cytoplasmic mRNA by
deadenylase enzymes is a critical step in post-
transcriptional gene regulation. The ribonuclease
activity of deadenylase enzymes is attributed
to either a DEDD (Asp-Glu-Asp-Asp) or an
endonuclease–exonuclease–phosphatase domain.
Both domains require the presence of two Mg2+
ions in the active site. To facilitate the biochemical
analysis of deadenylase enzymes, we have
developed a fluorescence-based deadenylase
assay. The assay is based on end-point measure-
ment, suitable for quantitative analysis and can
be adapted for 96- and 384-well microplate
formats. We demonstrate the utility of the assay
by screening a chemical compound library, resulting
in the identification of non-nucleoside inhibitors
of the Caf1/CNOT7 enzyme, a catalytic subunit of
the Ccr4–Not deadenylase complex. These
compounds may be useful tools for the biochem-
ical analysis of the Caf1/CNOT7 deadenylase
subunit of the Ccr4–Not complex and indicate
the feasibility of developing selective inhibitors of
deadenylase enzymes using the fluorescence-
based assay.
INTRODUCTION
Accurate control of gene expression depends on the
precise regulation of mRNA levels by both transcriptional
and post-transcriptional mechanisms. A key step in the
post-transcriptional regulation of mRNA levels involves
the shortening of the poly(A) tail of cytoplasmic messen-
ger RNA (mRNA) by deadenylase enzymes (1–5). These
enzymes play an important role in mRNA turnover.
In addition, deadenylation may also impact on translation
as the relation between poly(A) tail length and transla-
tional efﬁciency is well established (6,7).
Around 10 deadenylases are encoded by the human
genome (2). The catalytic activity of deadenylases is
provided by either an endonuclease–exonuclease–
phosphatase (EEP) domain, or a DEDD (Asp-Glu-Asp-
Asp) fold. In both cases, deadenylation is dependent on
the presence of two Mg2+ ions in the active site (2).
Examples of EEP-type deadenylases include the circadian
deadenylase Nocturnin/CCRN4L and the mitochondrial
deadenylase PDE12 (5,8,9). In contrast, PARN, a
homodimeric deadenylase that also contains a cap-
binding domain, and Pan2, which forms a heterodimeric
complex with Pan3, contain a DEDD domain (4,5,10–15).
The composition of the Ccr4–Not complex, a major
deadenylase important for cytoplasmic mRNA degrad-
ation (16–19), is unusually intricate as compared with
other deadenylases (4,20,21). In addition to at least six
non-catalytic subunits, the complex contains two distinct
subunits with deadenylase activity: a Caf1 subunit con-
taining a DEDD domain, and a Ccr4 component
characterized by an EEP fold (4,22,23). Both enzymatic
subunits are tethered to the non-catalytic components via
the large subunit CNOT1. The centrally located MIF4G
domain of CNOT1 contains multiple helical repeats that
interact with the Caf1 catalytic subunit (24,25). In turn, a
helix/loop region of Caf1 binds via hydrophobic
interactions with the leucine-rich repeat domain of the
Ccr4 deadenylase subunit (24). In vertebrate cells, the
complexity of the Ccr4–Not deadenylase is further
increased by the occurrence of two highly similar Caf1
paralogues (encoded by either CNOT7 or CNOT8)
(26,27). Similarly, the CNOT6 and CNOT6L genes
encode two Ccr4 paralogues associated with the Ccr4–
Not complex in vertebrates (28). It is currently unclear
to what extent the catalytic components of the Ccr4–Not
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complex have redundant or unique roles in mRNA
deadenylation (29–31).
To obtain further insight into the cellular and physio-
logical roles of deadenylase enzymes, novel tools such
as potent, selective and cell-permeable inhibitors of
deadenylase enzymes are desirable. Such molecules would
be valuable as chemical probes and complement the use of
RNAi-based tools, as they would inhibit the enzymatic
activity rather than interfere with potential structural
roles of deadenylase enzymes. Towards this goal, we ﬁrst
developed a new ﬂuorescence-based deadenylase assay,
because the various assays currently available for the
biochemical analysis of deadenylase enzymes are time
consuming, and less suitable for quantitative analysis and
screening. For example, widely used gel-based assays based
on (oligonucleotide) substrates labelled with ﬂuorescent or
radioactive moieties are difﬁcult to quantify and are labori-
ous. In contrast, quantitative assays based on methylene
blue colourimetry are insensitive and require high protein
and substrate concentrations (32,33). Finally, recently
developed quantitative assays based on size-exclusion
chromatography also have limited sensitivity, require
relatively large reaction volumes and are not suitable for
high-throughput screening (34). The ﬂuorescence-based,
quantitative deadenylase assay described here is based on
end-point measurement and suitable for 96- and 384-well
microplate formats. To show the usefulness of the assay,
we screened a small chemical compound library and
identiﬁed several inhibitors of the Caf1/CNOT7 enzyme.
These compounds may be useful tools for the biochemical
analysis of the Caf1/CNOT7 deadenylase subunit of
the Ccr4–Not complex and indicate the feasibility of
developing small molecule inhibitors of Mg2+-dependent
ribonuclease enzymes as well as the suitability of the ﬂuor-
escence-based deadenylase assay for the screening of
compound libraries.
MATERIALS AND METHODS
Plasmids and DNA cloning
A codon-optimized cDNA encoding human Caf1/CNOT7
was generated and subcloned using standard procedures
into the bacterial expression plasmid pQE80L (Qiagen)
using the BamHI and SalI restriction sites. A codon-
optimized cDNA fragment encoding human Ccr4/
CNOT6L lacking the amino terminal leucine-rich re-
peat domain (amino acids 1–155) was obtained using
standard polymerase chain reaction techniques and
cloned into the multiple cloning site of pQE80L
(Qiagen) using the BamHI and SalI restriction endonucle-
ases. The absence of mutations and the appropriate
reading frame were conﬁrmed by DNA sequencing. The
PARN expression plasmid (pET33PARN) has been
described previously (35). Site-directed mutations to
inactivate the active sites (D40A, CNOT7, E240A,
CNOT6L, D28A and PARN) were introduced using
standard protocols (Stratagene Quikchange).
Oligonucleotides used for site-directed mutagenesis were
designed using the online PrimerX tool (http://www.
bioinformatics.org/primerx/).
Protein expression and puriﬁcation
The human Caf1/CNOT7 deadenylase enzyme was
puriﬁed from Escherichia coli strain BL21 (DE3). Cells
were grown in Lysogeny Broth (LB) medium containing
50 mg/ml ampicillin (2 l) at 37C with vigorous shaking
until the optical density (600 nm) was between 0.6 and
0.8. Expression was then induced by the addition of
0.2mM isopropyl b-D-1-thiogalactopyranoside for 3 h at
30C, or overnight at room temperature. Cells were har-
vested by centrifugation (6000 rpm) using a Sorvall SLC-
6000 SUPER-LITE rotor at 4C for 15min. The super-
natant was discarded and the cell pellet was resuspended
in 30ml ice-cold extraction buffer (20mM Tris–HCl pH
7.8, 500mM NaCl, 10% glycerol, 2mM b-
mercaptoethanol). Cells were frozen and kept at 80C
until further use. After thawing the bacterial suspension,
the cells were lysed on ice using a Qsonica XL2000
sonicator (amplitude: 40%) using ﬁve 30 s on/30 s off
cycles. The crude lysate was centrifuged in a Sorvall SS-
34 rotor at 10 000 rpm, 4C for 30min to remove insoluble
material and stored at 80C until further use.
The hexahistidine-tagged Caf1/CNOT7 protein was
puriﬁed in a single step using HisTrap columns (GE Life
Science; 1ml bed volume) at 4C. The soluble lysate was
applied to the column using a syringe at an approximate
ﬂow rate of 2–3 drops per second (>1ml/min).
Subsequently, the column was washed using a syringe
ﬁlled with 10ml wash buffer (20mM Tris–HCl pH 7.8,
500mM NaCl, 10% glycerol, 2mM b-mercaptoethanol,
10mM imidazole) and ﬁnally, eluted with 5ml elution
buffer (20mM Tris–HCl pH 7.8, 500mM NaCl, 10%
glycerol, 2mM b-mercaptoethanol, 250mM imidazole),
which was collected in 1ml fractions. Elution fractions
were analysed by sodium dodecyl sulphate–polyacryl-
amide gel electrophoresis SDS–PAGE and coomassie
staining (Invitrogen Bio-Safe Staining kit) and peak
fractions used. Ccr4/CNOT6L was expressed and
puriﬁed from E. coli using a similar procedure. The
PARN enzyme was puriﬁed by immobilized metal
afﬁnity chromatography as described before with minor
modiﬁcations (35).
Oligonucleotides
Desalted oligonucleotides used as RNA substrate or DNA
probe were purchased from Sigma Genosys. Alternatively,
high performance liquid chromatography puriﬁed oligo-
nucleotides were purchased from Eurogentec. The 16-mer
RNA substrate oligonucleotide (50-CCU UUC CAA AAA
AAA A-30) contained a 50 ﬂuorescein (Flc) group. The
DNA probe (50-TTT TTT TTT GGA AAG G-30)
contained a 30 tetramethylrhodamine (TAMRA) or a 30
black hole quencher (BHQ)-1 modiﬁcation.
Assay conditions
Standard reaction conditions for deadenylase assays were:
20mM Tris–HCl pH 7.9, 50mM NaCl, 2mM MgCl2,
10% glycerol, 1mM b-mercaptoethanol and 1.0 mM 50-
Flc-labelled RNA substrate in nuclease-free water.
For gel-based detection of ribonuclease activity,
deadenylase reactions (10 ml) were incubated at 30C for











60min, stopped by the addition of 12 ml RNA loading
buffer [95% formamide, 0.025% bromophenol blue,
0.025% xylene cyanol FF, 0.025% sodium
dodecylsulphate and 5mM ethylenediaminetetraacetic
acid (EDTA)] and heated for 3min at 85C. A small
sample of the RNA mixture (3ml) was analysed by
denaturing PAGE using a 20% acrylamide:bisacrylamide
(19:1) gel containing 50% (w/v) urea. Polyacrylamide gels
(8 8 cm; Invitrogen Xcell system) were pre-run for
30min at 200V before sample loading. Flc-labelled
RNA was visualized by epiﬂuorescence using a Fujiﬁlm
LAS-4000 imager equipped with an Epi-Blue illuminator
(460 nm).
For ﬂuorescence-based detection of nuclease activity,
deadenylase reactions (10–20 ml) were incubated at 30C
for 60min and stopped by the addition of an equal volume
of probe mix containing 1% SDS, and a 5-fold molar
excess of 30-labelled DNA probe. Fluorescence intensity
was measured at 25C (sensitivity setting 70–90) using a
BioTek Synergy HT plate reader with 96 or 384 U-shaped
black multi-well plates. Filter sets used were: 485±20nm
(excitation) and 528±20nm (emission). Data analysis
and curve-ﬁtting were carried out using Microsoft Excel
2007 and Graphpad Prism 5.0.
HeLa cytoplasmic extract (S-100 fraction) was pur-
chased from Boston Biochem (cat no F-372, 5mg/ml).
Virtual screening
In order to prioritize candidates from our compound
collection as likely inhibitors of the Caf1/CNOT7
enzyme, we applied virtual library screening. This collec-
tion (University of Nottingham Managed Chemical
Compound Collection, MCCC) contains a highly
diverse set of 83 086 lead-like compounds. A database
containing the chemical structures of the MCCC com-
pounds was prepared for virtual screening using the
LigPrep and Epik modules of the Schro¨dinger (www.
schrodinger.com) small-molecule drug discovery
software suite (36) in order to standardize protonation
states and to generate 3D conformers of the molecules.
The coordinates of an X-ray crystal structure of the
Caf1–NOT1 complex (25) (Protein Data Bank entry
4GMJ, chain C) were used to construct a docking
receptor with Sybyl 8.0 (www.tripos.com) software.
Compounds were docked to this receptor using the
genetic optimization for ligand docking (GOLD)(37)
program (www.ccdc.cam.ac.uk) in standard parameter
mode. Docked compound poses were assessed and
ranked using Goldscore fitness scores, which ranged
from 30 to 88, with high scores (>77) predicting com-
pounds with likely afﬁnity for the active site of the Caf1
enzyme. The top 11% of virtual hits were rescored
exhaustively and a total of 1440 predicted hits were
selected for bioassay based on fitness scores and plausible
binding modes by visual inspection.
Automated screening
Compounds (10mM in dimethyl sulphoxide, DMSO)
were stored in a dry, inert environment at 20C and
dispensed in 96-well plates using an automated facility
(TTP Labtech Technology). Compounds were diluted to
0.5mM using 20% DMSO/water. Aliquots (4 ml; 25%
DMSO/water) were transferred to black U-well 384-well
plates (Greiner Bio-One) and subsequent automated
screening was carried out using a Biomek 3000 liquid
handler (Beckman Coulter). After addition of enzyme
(8ml containing 1.0 mM Caf1/CNOT7, 50mM Tris–HCl
pH 7.9, 125mM NaCl, 5mM MgCl2, 25% glycerol,
2.5mM b-mercaptoethanol), plates were left at room
temperature for 15min before the addition of RNA sub-
strate (8 ml). The composition of the ﬁnal reaction
mixture was: 0.4 mM Caf1/CNOT7, 20mM Tris–HCl
pH 7.9, 50mM NaCl, 2mM MgCl2, 10% glycerol,
1mM b-mercaptoethanol, 5% DMSO, 100 mM library
compound. After incubation at 30C for 60min, 20 ml
probe mix (5 mM DNA probe, 1% SDS, 20mM Tris–
HCl pH 8.0, 0.5mM EDTA) was added. Fluorescence
was measured using a BioTek Synergy HT plate reader
as described above.
RESULTS
Design of a ﬂuorescence-based deadenylase assay
Based on the ﬁndings that short RNA oligonucleotides are
substrates of deadenylase enzymes in vitro (22,30,38), we
designed a substrate detection method based on ﬂuores-
cence resonance energy transfer (FRET). The two-stage
deadenylase assay contained three key components:
(i) the (puriﬁed) enzyme, (ii) a 50 ﬂuorophore-labelled
RNA substrate and (iii) a DNA probe containing a
30 ﬂuorophore. We initially used a Flc-labelled RNA sub-
strate and a complementary DNA probe labelled with
TAMRA, which form a well characterized ‘FRET pair’
(Figure 1A). The principle of the assay is the complemen-
tarity of the probe and the RNA substrate in the absence
of deadenylase activity, resulting in close proximity of the
Flc and TAMRA ﬂuorophores, which prevents ﬂuores-
cence of the Flc moiety. In contrast, efﬁcient annealing
of the DNA probe is prevented when the substrate is
degraded, thus allowing detection of Flc-mediated ﬂuor-
escence (Figure 1A).
The principle of the assay was tested using puriﬁed
Caf1/CNOT7, a catalytic subunit of the Ccr4–Not
deadenylase complex. Wild-type and catalytically
inactive versions of human Caf1/CNOT7 containing an
amino-terminal hexahistidine tag were expressed in
E. coli and puriﬁed using immobilized-metal afﬁnity puri-
ﬁcation (Figure 1B). The catalytically inactive version
of Caf1/CNOT7 contained the amino acid substitution
Asp-40!Ala, which interferes with chelation of Mg2+
ions in the active site (22,39,40). Using a gel-based
assay, degradation of the substrate was observed when
wild-type Caf1/CNOT7 was incubated with a 50 Flc-
labelled 16-mer oligonucleotide substrate containing a 30
stretch of nine adenosine residues. The deadenylase
activity was speciﬁc, because it was not observed in the
presence of catalytically inactive Caf1/CNOT7 D40A
(Figure 1C).
Next, we carried out the ﬂuorescence-based detection
of deadenylase activity (Figure 1D). After incubation of











the Flc-labelled substrate with Caf1/CNOT7, we added a
solution containing sodium dodecylsulphate (0.5% ﬁnal
concentration) to inhibit any residual activity of the
Caf1/CNOT7 enzyme (data not shown) and a 5-fold
molar excess of the TAMRA-labelled DNA probe. As
shown, ﬂuorescence was detected after incubation with
wild-type Caf1/CNOT7 and was highly reproducible.
In contrast, no ﬂuorescence was observed when the
substrate was incubated with inactive Caf1/CNOT7,
even in the presence of high enzyme concentrations or
when incubated for up to 1 h (Figure 1D and E).
The signal/background ratio was not improved by
replacing the TAMRA ﬂuorophore of the probe with
a BHQ (Supplementary Figure S1A). To optimize the
substrate/probe ratio, we used varying probe concentra-
tions. This indicated that a three-fold probe excess was
sufﬁcient to obtain a maximum signal/background ratio
(Supplementary Figure S1B).
Kinetic analysis of deadenylation by Caf1/CNOT7
To evaluate the suitability of the ﬂuorescence-based
deadenylase assay for quantitative analysis, we carried
out a kinetic analysis of the Caf1/CNOT7 enzyme
activity. Thus, we incubated a ﬁxed amount of Caf1/
CNOT7 with increasing substrate concentrations and
measured the ﬂuorescence as a function of time
(Figure 2A). The results were consistent with multiple
substrate turnover events per enzyme. After obtaining
the initial rate of reaction by linear regression, the
substrate concentration was plotted versus the initial
rate of reaction (Figure 2B). By using non-linear
regression, we derived the Km constant of the Caf1/
CNOT7 enzyme for its oligonucleotide substrate
(10.6±2.9 mM). Similar values were obtained by linear
regression analysis using a Lineweaver–Burke plot
(Figure 2B, inset).
Figure 1. Principle of the ﬂuorescence-based deadenylase assay. (A) Schematic diagram of the ﬂuorescence-based deadenylase assay. The assay is
based on a 50 Flc-labelled RNA oligonucleotide substrate. After incubation of the substrate in the presence of a deadenylase enzyme, the reaction is
stopped and a 30 TAMRA-labelled DNA oligonucleotide probe complementary to the RNA substrate is added. Flc ﬂuorescence of intact substrate
is quenched upon probe hybridization because of the close proximity of the TAMRA ﬂuorophore. In contrast, the TAMRA-labelled probe cannot
hybridize to the Flc-labelled reaction product allowing detection of Flc ﬂuorescence. (B) Puriﬁed enzymes used for assay development. Wild-type
Caf1/CNOT7 and inactive Caf1/CNOT7 containing the amino acid substitution D40A were expressed as His-tagged proteins in E. coli and puriﬁed
using immobilized-metal afﬁnity chromatography. Puriﬁed proteins (3mg) were separated by 12% SDS–PAGE and stained with coomassie.
(C) Gel-based deadenylase assay. Equal amounts of wild-type and inactive Caf1/CNOT7 (0.4 mM) were incubated with 50 Flc-labelled substrate
(1mM). After incubation (60min), the substrate RNA was subjected to denaturing PAGE and visualized using epiﬂuorescence. Indicated are the
intact RNA substrates containing nine 30 adenylate residues (A9) and the 8-mer reaction product containing a single 30 adenylate residue (A1).
(D) Fluorescence-based measurement of deadenylase activity. The indicated amount of wild-type and inactive (D40A) Caf1/CNOT7 protein was
incubated with Flc-labelled substrate (1 mM). After incubation (60min), a 5-fold molar excess of the 30 TAMRA-labelled probe was added before
ﬂuorescence was measured. (E) Measurement of ﬂuorescence as a function of time. Wild-type and inactive D40A Caf1/CNOT7 (0.4 mM) were
incubated with Flc-labelled substrate (1 mM). After the indicated time, a 5-fold molar excess of the 30 TAMRA-labelled probe was added before
ﬂuorescence was measured. Error bars indicate the standard error of the mean (n=3).











Application of the ﬂuorescence-based deadenylase assay
for screening
To demonstrate the usefulness of the assay, we adapted
the ﬂuorescence-based assay for use with 384-well
microwell plates and screened a compound library. The
screening assay comprises four pipetting steps, which is
compatible with automated liquid handling. First, a
solution containing a test compound (in 25% DMSO)
Figure 2. Quantitative analysis of Caf1/CNOT7 enzyme kinetics. (A) Measurement of ﬂuorescence as a function of time using the indicated oligo-
nucleotide substrate concentrations. Reactions contained 0.4 mM Caf1/CNOT7 enzyme. Error bars indicate the standard error of the mean (n=3).
Fluorescence was normalized by subtraction of background ﬂuorescence observed in the absence of enzyme. (B) Kinetic data from panel (A) were
plotted to estimate the Km by curve ﬁtting of the Michaelis–Menten equation (Km=10.6±2.9 mM). The inset shows the Lineweaver–Burk plot of
the kinetic data from panel (A). Curve ﬁtting was carried out using Graphpad Prism. Error bars indicate the standard error of the mean.
Figure 3. Identiﬁcation of small molecule inhibitors of Caf1/CNOT7 using a ﬂuorescence-based deadenylase assay. (A) Evaluation of the ﬂuores-
cence-based deadenylase assay for screening by Z factor analysis. The mean value of the Z factor is 0.88±0.02 (n=4). (B) Screening of a library of
1440 compounds. The compounds were dispensed in ﬁve 384-well plates and pre-incubated with Caf1/CNOT7 enzyme for 15min at room tempera-
ture. After addition of RNA substrate (ﬁnal concentration: 0.4 mM Caf1/CNOT7 enzyme, 100mM library compound, 1.0 mM substrate in a reaction
volume of 20 ml), reactions were incubated for 60min. Reactions were stopped by the addition of 20 ml of a solution containing 1.0% SDS and a
5-fold molar excess of probe. Dots indicate ﬂuorescence of each well containing a library compound. Also indicated is the mean background
ﬂuorescence (solid line). Dotted lines indicate three standard deviations from the mean of reactions containing library compounds or of the
mean background ﬂuorescence, respectively.











was dispensed into the microwell plates. Subsequently, a
solution containing the Caf1/CNOT7 enzyme was added
and incubated for 15min at room temperature. After
addition of the substrate, the reactions were incubated
for 60min at 30C. Finally, reactions were terminated by
the addition of SDS and the DNA probe before measure-
ment of ﬂuorescence. We established that the signal
remains stable for up to 7 days when the reactions are
kept in the dark at room temperature, which will facilitate
the analysis of large numbers of plates in parallel
(Supplementary Figure S2). After optimization of auto-
mated liquid handling steps, the suitability of the assay
for screening was conﬁrmed by determination of the
Z factor (0.88±0.02, n=4), which indicates that the
assay is of high quality (Figure 3A).
Subsequently, we assessed the feasibility of identifying
small-molecule inhibitors of Caf1/CNOT7 by screening a
library of 1440 compounds, which were selected based
on a preliminary virtual screening of 83 086 compounds
(Figure 3B). This automated procedure led to 11
compounds that were analysed further. Two compounds
precipitated and were discarded. Three compounds
had very weak inhibitory activity (estimated IC50>
500mM) and were not investigated further. Of the remain-
ing six, ﬁve compounds had IC50 values between 100 and
250mM as determined by using the ﬂuorescence-based
deadenylase assay (Figure 4A and B). In addition, we
identiﬁed one more potent compound with a low
micromolar IC50 value (Figure 4A and B). The analysis
of the structure–activity relationships of a set of analogues
of the latter compound is currently underway and will
be reported elsewhere.
To ensure that the identiﬁed compounds were bona ﬁde
inhibitors of the Caf1/CNOT7 enzyme, and to exclude the
possibility that the compounds were identiﬁed based on
interference with the ﬂuorescent measurements, we used
a gel-based assay. Thus, we incubated the Caf1/CNOT7
enzyme with the oligonucleotide substrate in the presence
or absence of the compounds. As expected, Caf1/CNOT7
deadenylated the oligonucleotide substrate, whereas the
substrate remained intact in control reactions that did
not contain Caf1/CNOT7 enzyme. Importantly, removal
of 30 adenylate residues was greatly reduced in the
presence of the identiﬁed compounds (Figure 5).
Together, these results indicate the suitability of the ﬂuor-
escence-based deadenylase assay for screening as well as
the feasibility of identifying small molecule inhibitors of
the Caf1/CNOT7 enzyme.
Selective inhibition of the Caf1/CNOT7 deadenylase
To assess whether the identiﬁed compounds are selective
for the Caf1/CNOT7 enzyme, or whether they are
more general inhibitors of deadenylase enzymes, we
evaluated the effect of the compounds on the activity of
the Ccr4/CNOT6L and PARN enzymes. Thus, we
incubated these enzymes in the presence or absence of
300mM of the inhibitors. As shown, compounds NCC-
00001590 and NCC-00039069 only inhibited Caf1/
CNOT7 and did not inhibit the activity of Ccr4/
CNOT6L or PARN (Figure 6A and D). In contrast,
compounds NCC-00007277,NCC-00019223 and NCC-
00037292 displayed less selectivity and partially inhibited
the activity of PARN and Ccr4/CNOT6L, respectively
(Figure 6B, C and F). Finally, NCC-00010651 inhibited
Figure 4. Determination of IC50 values of small-molecule inhibitors of
Caf1/CNOT7. (A) Determination of IC50 values. Compounds were pre-
incubated with Caf1/CNOT7 for 15min at room temperature, followed
by the addition of RNA substrate. After incubation (60min at 30C),
reactions were stopped by the addition of SDS and a 5-fold molar
excess of probe. Shown are representative experiments. Error bars
indicate the standard error of the mean. (B) Structures of inhibitors
with IC50 values <250 mM. The chemical structure of NCC-00037292
will be reported elsewhere. The IC50 values shown (± standard error of
the mean) are derived from at least three independent replicate
experiments.











all three deadenylase enzymes, albeit no complete inhib-
ition of PARN and Ccr4/CNOT6L was obtained
(Figure 6E). Taken together, these results indicate that
selective inhibition of deadenylase enzymes, speciﬁcally
of the Caf1/CNOT7 enzyme, with small molecules is
feasible. Moreover, the availability of the ﬂuorescence-
based deadenylase assay opens up routes for the screening
of more extensive compound libraries using automated
screening.
Fluorescence-based detection of 30 exonuclease activity in
complex mixtures
To assess the usability of the assay and the identiﬁed
inhibitors in more complex conditions, we used HeLa
S-100 cytoplasmic extracts. First, we incubated
increasing concentrations of the S-100 fraction with
the Flc-labelled RNA substrate and analysed the
reaction products by gel electrophoresis (Figure 7A).
At high concentrations (0.5mg/ml), complete degrad-
ation beyond the stretch of nine adenosine residues
was observed, as expected, based on the presence of
other ribonucleases in the extract. However, a fraction
of the RNA substrate appeared resistant against deg-
radation, presumably because of RNA-binding proteins.
When we used the ﬂuorescence-based detection, we
observed a clear dose–response effect with >90% of
maximal signal observed in the presence of 0.5mg/ml
S-100 fraction (Figure 7B). To determine the activity
of the identiﬁed inhibitors of Caf1 in the context of
Figure 6. Selective inhibition of the Caf1/CNOT7 deadenylase. The activity of the Caf1/CNOT7, Ccr4/CNOT6L and PARN deadenylase enzymes
was assessed in the presence of 300mM (ﬁnal concentration) of compound (A) NCC-00001590, (B) NCC-00007277, (C) NCC-00019223, (D) NCC-
00039069, (E) NCC-00010651 and (F) NCC-00037292 (100 mM). Enzymes were pre-incubated with the indicated compounds at room temperature for
15min. After addition of Flc-labelled substrate RNA, reactions were incubated at 30C for 60min. Fluorescence was measured after addition of a
mixture containing SDS (0.5% ﬁnal concentration) and a 5-fold molar excess of TAMRA-labelled probe. Error bars indicate the standard error of
the mean (n=3).
Figure 5. Validation of inhibitory activity using gel-based product
analysis. The indicated compounds (NCC-00001590, NCC-00007277,
NCC-00019223, NCC-00039069, NCC-00010651, 300mM; NCC-
00037292, 100mM, ﬁnal concentration) were incubated with
puriﬁed Caf1/CNOT7 enzyme (0.4 mM) and the 50 Flc-labelled oligo-
nucleotide substrate (1.0 mM). After incubation (30C for 60min),
reactions were inactivated by heating. Products were separated by
denaturing PAGE and directly visualized by epiﬂuorescence.
Indicated are the intact RNA substrates containing nine 30 adenylate
residues (A9) and the 8-mer reaction product containing a single 30
adenylate residue (A1).











a complex mixture, we used a subsaturating amount of
S-100 fraction (0.05mg/ml). Comparison of the signal
obtained in the absence or presence of S-100 fraction
indicated that a high background was observed when
using a crude extract. This is consistent with the
observation that a fraction of the RNA substrate
remains refractory to degradation in these conditions.
Although addition of DMSO (5%) did not signiﬁcantly
inhibit activity of the extract, partial inhibition was
observed in the presence of three compounds. The
strongest effect was observed with compounds NCC-
00007277 and NCC-00037292 (Figure 7C).
Interestingly, these compounds partially inhibit PARN
(Figure 6), which is the predominant deadenylase in cell
extracts (41,42).
DISCUSSION
Here we report a new method for the analysis of the
biochemical activity of deadenylase enzymes. The ﬂuores-
cence-based deadenylase assay is sensitive, can be used for
quantitative analysis and is suitable for miniaturization
using 96- and 384-well plates. We believe that this assay
has signiﬁcant advantages for the quantitative evaluation
of deadenylase enzymes over existing approaches, such as
analyses based on gel electrophoresis, methylene blue
colourimetry or size-exclusion chromatography (32–34).
Due to the sensitivity of the ﬂuorescence-based deadeny-
lase assay, activity can be detected at much lower con-
centrations and in smaller reaction volumes as compared
with colourimetry- or chromatography-based assays.
Moreover, the assay is fast and much less laborious as
compared with methods involving gel electrophoresis
or chromatography. Combined with its suitability for
plate-based formats, this allows the evaluation of a large
number of reactions in parallel with less effort as
compared with any of the alternative methods.
We demonstrate the use of the ﬂuorescence-based
deadenylase assay for the screening of compound libraries
and identiﬁed one compound with relatively high afﬁnity
(IC50 between 10 and 20 mM) and ﬁve inhibitors with rela-
tively low potency (IC50 around 100 mM). Despite their
low potency, these compounds will be useful for the bio-
chemical analysis of deadenylase enzymes. The identiﬁed
inhibitors are structurally unrelated, but, based on prelim-
inary molecular modelling analysis, we believe that all
compounds bind in the active site thereby blocking inter-
actions with the RNA substrate. A process to derive
a structure–activity relationship is currently underway
for the most potent compound NCC-00037292.
In addition, the screening of more extensive compound
collections in combination with the synthesis and evalu-
ation of novel chemical entities will likely result in more
potent inhibitors of the Caf1/CNOT7 deadenylase enzyme
that can be appraised in cell-based assays. This will
also provide more detail about binding to the Caf1
deadenylase and the mechanism of inhibition.
Recently, Balatsos and co-workers (43,44) reported
inhibitors of the PARN deadenylase, which—as is the
case with Caf1/CNOT7—contains a DEDD domain. In
contrast to the compounds reported here, the reported
inhibitors of the PARN enzyme were nucleoside ana-
logues with Ki values ranging between 20 and >500 mM.
It will be of interest to establish whether these nucleoside
analogues are selective inhibitors of PARN or whether
they also inhibit other deadenylases such as Caf1/CNOT7.
Figure 7. Fluorescence-based detection of 30 exonuclease activity in
complex mixtures. (A) Gel-based assay. Increasing amounts of a
HeLa S-100 cytoplasmic extract was incubated with 50 Flc-labelled sub-
strate (1mM). After incubation (60min), the substrate RNA was sub-
jected to denaturing PAGE and visualized using epiﬂuorescence.
Indicated are the intact RNA substrates containing nine 30 adenylate
residues (A9) and the deadenylated product (A1). (B) Fluorescence-
based measurement of exonuclease activity. The indicated amount of
HeLa S-100 fraction was incubated with Flc-labelled substrate (1 mM).
After incubation (60min), a 5-fold molar excess of the 30 TAMRA-
labelled probe was added before ﬂuorescence was measured. (C) The
activity of the S-100 fraction was assessed in the presence of NCC-
00001590, NCC-00007277, NCC-00019223, NCC-00039069 and NCC-
00010651 (300 mM) or NCC-00037292 (100 mM). *P< 0.05, **P< 0.01.
Error bars indicate the standard error of the mean (n=3).











In conclusion, we believe that the ﬂuorescence-based
deadenylase assay described here complements existing
assays for the quantitative, biochemical analysis of
deadenylase enzymes, e.g. when comparing the activities
of wild-type enzymes with those containing amino acid
substitutions. By using the assay for the screening of a
compound library, we demonstrate the utility of the
assay as well as the feasibility of developing selective
inhibitors of the Caf1/CNOT7 deadenylase subunit of
the Ccr4–Not complex. Such inhibitors, together with
inhibitors of other Mg2+-dependent ribonucleases, such
as those inhibiting PARN (43,44), will be highly useful
tools as chemical probes that complement existing
resources available for the study of post-transcriptional
gene regulation.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
Prof. Anders Virtanen (University of Uppsala, Sweden) is
gratefully acknowledged for his generous gift of plasmid
pET33-PARN.
FUNDING
The Medical Research Council [G1100205]; Islamic
Development Bank [merit scholarship programme to
M.M.]. Funding for open access charge: University of
Nottingham; Research Councils UK (MRC).
Conﬂict of interest statement. None declared.
REFERENCES
1. Garneau,N.L., Wilusz,J. and Wilusz,C.J. (2007) The highways and
byways of mRNA decay. Nat. Rev. Mol. Cell Biol., 8, 113–126.
2. Goldstrohm,A.C. and Wickens,M. (2008) Multifunctional
deadenylase complexes diversify mRNA control. Nat. Rev. Mol
Cell Biol., 9, 337–344.
3. Parker,R. and Song,H. (2004) The enzymes and control of
eukaryotic mRNA turnover. Nat. Struct. Mol. Biol., 11, 121–127.
4. Wahle,E. and Winkler,G.S. (2013) RNA decay machines:
Deadenylation by the Ccr4-Not and Pan2-Pan3 complexes.
Biochim. Biophys. Acta, 1829, 561–570.
5. Godwin,A.R., Kojima,S., Green,C.B. and Wilusz,J. (2013) Kiss
your tail goodbye: The role of PARN, Nocturnin, and Angel
deadenylases in mRNA biology. Biochim. Biophys. Acta, 1829,
571–579.
6. Lackner,D.H., Beilharz,T.H., Marguerat,S., Mata,J., Watt,S.,
Schubert,F., Preiss,T. and Bahler,J. (2007) A network of multiple
regulatory layers shapes gene expression in ﬁssion yeast. Mol.
Cell, 26, 145–155.
7. Munroe,D. and Jacobson,A. (1990) mRNA poly(A) tail, a 30
enhancer of translational initiation. Mol. Cell Biol., 10, 3441–3455.
8. Baggs,J.E. and Green,C.B. (2003) Nocturnin, a deadenylase in
Xenopus laevis retina: a mechanism for posttranscriptional
control of circadian-related mRNA. Curr. Biol., 13, 189–198.
9. Rorbach,J., Nicholls,T.J. and Minczuk,M. (2011) PDE12 removes
mitochondrial RNA poly(A) tails and controls translation in
human mitochondria. Nucleic Acids Res., 39, 7750–7763.
10. Virtanen,A., Henriksson,N., Nilsson,P. and Nissbeck,M. (2013)
Poly(A)-speciﬁc ribonuclease (PARN): an allosterically regulated,
processive and mRNA cap-interacting deadenylase. Crit. Rev.
Biochem. Mol. Biol., 48, 192–209.
11. Dehlin,E., Wormington,M., Korner,C.G. and Wahle,E. (2000)
Cap-dependent deadenylation of mRNA. EMBO J., 19,
1079–1086.
12. Gao,M., Wilusz,C.J., Peltz,S.W. and Wilusz,J. (2001) A novel
mRNA-decapping activity in HeLa cytoplasmic extracts is
regulated by AU-rich elements. EMBO J., 20, 1134–1143.
13. Martinez,J., Ren,Y.G., Nilsson,P., Ehrenberg,M. and Virtanen,A.
(2001) The mRNA cap structure stimulates rate of poly(A)
removal and ampliﬁes processivity of degradation. J. Biol. Chem.,
276, 27923–27929.
14. Brown,C.E., Tarun,S.Z. Jr., Boeck,R. and Sachs,A.B. (1996)
PAN3 encodes a subunit of the Pab1p-dependent poly(A)
nuclease in Saccharomyces cerevisiae. Mol. Cell Biol., 16,
5744–5753.
15. Uchida,N., Hoshino,S. and Katada,T. (2004) Identiﬁcation of a
human cytoplasmic poly(A) nuclease complex stimulated by
poly(A)-binding protein. J. Biol. Chem., 279, 1383–1391.
16. Tucker,M., Valencia-Sanchez,M.A., Staples,R.R., Chen,J.,
Denis,C.L. and Parker,R. (2001) The transcription factor
associated Ccr4 and Caf1 proteins are components of the major
cytoplasmic mRNA deadenylase in Saccharomyces cerevisiae.
Cell, 104, 377–386.
17. Yamashita,A., Chang,T.C., Yamashita,Y., Zhu,W., Zhong,Z.,
Chen,C.Y. and Shyu,A.B. (2005) Concerted action of poly(A)
nucleases and decapping enzyme in mammalian mRNA turnover.
Nat. Struct. Mol. Biol., 12, 1054–1063.
18. Temme,C., Zaessinger,S., Meyer,S., Simonelig,M. and Wahle,E.
(2004) A complex containing the CCR4 and CAF1 proteins is
involved in mRNA deadenylation in Drosophila. EMBO J., 23,
2862–2871.
19. Temme,C., Zhang,L., Kremmer,E., Ihling,C., Chartier,A., Sinz,A.,
Simonelig,M. and Wahle,E. (2010) Subunits of the Drosophila
CCR4-NOT complex and their roles in mRNA deadenylation.
RNA, 16, 1356–1370.
20. Bartlam,M. and Yamamoto,T. (2010) The structural basis for
deadenylation by the CCR4-NOT complex. Protein Cell, 1,
443–452.
21. Collart,M.A. and Panasenko,O.O. (2012) The Ccr4–not complex.
Gene, 492, 42–53.
22. Horiuchi,M., Takeuchi,K., Noda,N., Muroya,N., Suzuki,T.,
Nakamura,T., Kawamura-Tsuzuku,J., Takahasi,K., Yamamoto,T.
and Inagaki,F. (2009) Structural basis for the antiproliferative
activity of the Tob-hCaf1 complex. J. Biol. Chem., 284,
13244–13255.
23. Wang,H., Morita,M., Yang,X., Suzuki,T., Yang,W., Wang,J.,
Ito,K., Wang,Q., Zhao,C., Bartlam,M. et al. (2010) Crystal
structure of the human CNOT6L nuclease domain reveals strict
poly(A) substrate speciﬁcity. EMBO J., 29, 2566–2576.
24. Basquin,J., Roudko,V.V., Rode,M., Basquin,C., Seraphin,B. and
Conti,E. (2012) Architecture of the nuclease module of the yeast
Ccr4-not complex: the Not1-Caf1-Ccr4 interaction. Mol. Cell, 48,
207–218.
25. Petit,A.P., Wohlbold,L., Bawankar,P., Huntzinger,E., Schmidt,S.,
Izaurralde,E. and Weichenrieder,O. (2012) The structural basis
for the interaction between the CAF1 nuclease and the NOT1
scaffold of the human CCR4-NOT deadenylase complex. Nucleic
Acids Res., 40, 11058–11072.
26. Albert,T.K., Lemaire,M., van Berkum,N.L., Gentz,R.,
Collart,M.A. and Timmers,H.T. (2000) Isolation and
characterization of human orthologs of yeast CCR4-NOT
complex subunits. Nucleic Acids Res., 28, 809–817.
27. Draper,M.P., Salvadore,C. and Denis,C.L. (1995) Identiﬁcation of
a mouse protein whose homolog in Saccharomyces cerevisiae is
a component of the CCR4 transcriptional regulatory complex.
Mol. Cell Biol., 15, 3487–3495.
28. Dupressoir,A., Morel,A.P., Barbot,W., Loireau,M.P., Corbo,L.
and Heidmann,T. (2001) Identiﬁcation of four families of
yCCR4- and Mg2+-dependent endonuclease-related proteins in
higher eukaryotes, and characterization of orthologs of yCCR4
with a conserved leucine-rich repeat essential for hCAF1/hPOP2
binding. BMC Genomics, 2, 9.











29. Aslam,A., Mittal,S., Koch,F., Andrau,J.C. and Winkler,G.S.
(2009) The Ccr4-Not Deadenylase Subunits CNOT7 and CNOT8
Have Overlapping Roles and Modulate Cell Proliferation.
Mol. Biol. Cell, 20, 3840–3850.
30. Mittal,S., Aslam,A., Doidge,R., Medica,R. and Winkler,G.S.
(2011) The Ccr4a (CNOT6) and Ccr4b (CNOT6L) deadenylase
subunits of the human Ccr4-Not complex contribute to the
prevention of cell death and senescence. Mol. Biol. Cell, 22,
748–758.
31. Morita,M., Suzuki,T., Nakamura,T., Yokoyama,K., Miyasaka,T.
and Yamamoto,T. (2007) Depletion of mammalian CCR4b
deadenylase triggers elevation of the p27Kip1 mRNA level and
impairs cell growth. Mol. Cell Biol., 27, 4980–4990.
32. Cheng,Y., Liu,W.F., Yan,Y.B. and Zhou,H.M. (2006) A
nonradioactive assay for poly(a)-speciﬁc ribonuclease activity by
methylene blue colorimetry. Protein Pept. Lett., 13, 125–128.
33. Greiner-Stoeffele,T., Grunow,M. and Hahn,U. (1996) A general
ribonuclease assay using methylene blue. Anal. Biochem., 240,
24–28.
34. He,G.J. and Yan,Y.B. (2012) A deadenylase assay by size-
exclusion chromatography. PLoS One, 7, e33700.
35. Nilsson,P. and Virtanen,A. (2006) Expression and puriﬁcation of
recombinant poly(A)-speciﬁc ribonuclease (PARN). Int. J. Biol.
Macromol., 39, 95–99.
36. Sherman,W., Day,T., Jacobson,M.P., Friesner,R.A. and Farid,R.
(2006) Novel procedure for modeling ligand/receptor induced ﬁt
effects. J. Med. Chem., 49, 534–553.
37. Verdonk,M.L., Cole,J.C., Hartshorn,M.J., Murray,C.W. and
Taylor,R.D. (2003) Improved protein-ligand docking using
GOLD. Proteins, 52, 609–623.
38. Andersen,K.R., Jonstrup,A.T., Van,L.B. and Brodersen,D.E.
(2009) The activity and selectivity of ﬁssion yeast Pop2p are
affected by a high afﬁnity for Zn2+ and Mn2+ in the active site.
RNA, 15, 850–861.
39. Jonstrup,A.T., Andersen,K.R., Van,L.B. and Brodersen,D.E.
(2007) The 1.4-A crystal structure of the S. pombe Pop2p
deadenylase subunit unveils the conﬁguration of an active
enzyme. Nucleic Acids Res., 35, 3153–3164.
40. Liu,W.F. and Yan,Y.B. (2008) Biophysical and biochemical
characterization of recombinant human Pop2 deadenylase.
Protein Expr. Purif., 60, 46–52.
41. Astrom,J., Astrom,A. and Virtanen,A. (1991) In vitro
deadenylation of mammalian mRNA by a HeLa cell 30
exonuclease. EMBO J., 10, 3067–3071.
42. Korner,C.G. and Wahle,E. (1997) Poly(A) tail shortening by a
mammalian poly(A)-speciﬁc 30-exoribonuclease. J. Biol. Chem.,
272, 10448–10456.
43. Balatsos,N., Vlachakis,D., Chatzigeorgiou,V., Manta,S.,
Komiotis,D., Vlassi,M. and Stathopoulos,C. (2012) Kinetic and
in silico analysis of the slow-binding inhibition of human
poly(A)-speciﬁc ribonuclease (PARN) by novel nucleoside
analogues. Biochimie, 94, 214–221.
44. Balatsos,N.A., Vlachakis,D., Maragozidis,P., Manta,S.,
Anastasakis,D., Kyritsis,A., Vlassi,M., Komiotis,D. and
Stathopoulos,C. (2009) Competitive inhibition of human
poly(A)-speciﬁc ribonuclease (PARN) by synthetic
ﬂuoro-pyranosyl nucleosides. Biochemistry, 48, 6044–6051.
10 Nucleic Acids Research, 2013
 at U
niversity of N
ottingham
 on M
arch 11, 2014
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
